Figure 1
Figure 1. Phenotypic and functional characteristics of the T-cell products infused. (A) Phenotypic characteristics of T cells infused. CD3+, CD56+, and Tetramer+ cells are expressed as a percentage of total cells. CD8+, CD4+, CD62L+, and CD45RO+ cells are expressed as a percentage of CD3+ cells. (B) Function of T cells infused as assessed by chromium release assay. (Top left plot) An example of killing of recipient PHA blasts pulsed with CMV-pp65 pepmix (♦), HLA-B*0702 restricted (•), or HLA-B*3501 (▴) restricted CMV peptides as well as adenoviral hexon protein pepmix (■). Top right and bottom left plots show examples of killing of recipient PHA blasts pulsed with CMV-pp65 pepmix or HLA-B7–restricted CMV-peptide with more typical low-level killing of blasts pulsed with adenoviral hexon protein pepmix. In all 3 plots, typical absence of killing of unpulsed allo-PHA blasts (×) is seen.

Phenotypic and functional characteristics of the T-cell products infused. (A) Phenotypic characteristics of T cells infused. CD3+, CD56+, and Tetramer+ cells are expressed as a percentage of total cells. CD8+, CD4+, CD62L+, and CD45RO+ cells are expressed as a percentage of CD3+ cells. (B) Function of T cells infused as assessed by chromium release assay. (Top left plot) An example of killing of recipient PHA blasts pulsed with CMV-pp65 pepmix (♦), HLA-B*0702 restricted (•), or HLA-B*3501 (▴) restricted CMV peptides as well as adenoviral hexon protein pepmix (■). Top right and bottom left plots show examples of killing of recipient PHA blasts pulsed with CMV-pp65 pepmix or HLA-B7–restricted CMV-peptide with more typical low-level killing of blasts pulsed with adenoviral hexon protein pepmix. In all 3 plots, typical absence of killing of unpulsed allo-PHA blasts (×) is seen.

Close Modal

or Create an Account

Close Modal
Close Modal